Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/74027
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Verma, A. | - |
dc.contributor.author | Sanders, P. | - |
dc.contributor.author | MacLe, L. | - |
dc.contributor.author | Deisenhofer, I. | - |
dc.contributor.author | Morillo, C. | - |
dc.contributor.author | Chen, J. | - |
dc.contributor.author | Jiang, C. | - |
dc.contributor.author | Ernst, S. | - |
dc.contributor.author | Mantovan, R. | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | American Heart Journal, 2012; 164(1):1-12 | - |
dc.identifier.issn | 0002-8703 | - |
dc.identifier.issn | 1097-6744 | - |
dc.identifier.uri | http://hdl.handle.net/2440/74027 | - |
dc.description.abstract | <h4>Background</h4>The optimal ablation approach for patients with persistent atrial fibrillation (AF) remains unknown. In particular, it is unclear if pulmonary vein (PV) antral isolation (PVI) is sufficient as a lone strategy for persistent AF. Furthermore, if additional substrate ablation is to be added, the ideal approach to substrate ablation is yet to be determined.<h4>Objective</h4>The aim of this study is to determine the optimal strategy of catheter ablation of persistent AF by comparing the efficacy of 3 strategies: PVI vs PVI plus complex fractionated electrogram (CFE) ablation (PVI + CFE) vs PVI plus linear ablation (PVI + Lines).<h4>Study design</h4>The STAR AF II study (ClinicalTrials.gov NCT01203748) is a prospective, multicenter, randomized trial with a blinded assessment of outcomes. A total of 549 patients will be randomized in a 1:4:4 fashion to one of the investigation arms: PVI, PVI + CFE, and PVI + Lines, respectively. Patients undergoing a first-time ablation procedure for symptomatic, persistent AF that is refractory to at least 1 antiarrhythmic medication will be included. Persistent AF will be defined as a sustained episode lasting >7 days and <3 years. Patients with a left atrial parasternal size ≥60 mm will be excluded. The primary end point is freedom from documented AF >30 seconds at 18 months after 1 or 2 ablation procedures with or without antiarrhythmic medications.<h4>Conclusions</h4>The STAR AF II study is a randomized trial designed to evaluate the optimal approach for catheter ablation of persistent AF. | - |
dc.description.statementofresponsibility | Atul Verma, Prashanthan Sanders, Laurent Macle, Isabel Deisenhofer, Carlos A. Morillo, Jian Chen, Chen-yang Jiang, Sabine Ernst and Roberto Mantovan | - |
dc.language.iso | en | - |
dc.publisher | Mosby Inc | - |
dc.rights | © 2012, Mosby, Inc. All rights reserved. | - |
dc.source.uri | http://dx.doi.org/10.1016/j.ahj.2012.04.002 | - |
dc.subject | Humans | - |
dc.subject | Atrial Fibrillation | - |
dc.subject | Catheter Ablation | - |
dc.subject | Prospective Studies | - |
dc.subject | Single-Blind Method | - |
dc.subject | Randomized Controlled Trials as Topic | - |
dc.title | Substrate and trigger ablation for reduction of atrial fibrillation trial - Part II (STAR AF II): design and rationale | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/j.ahj.2012.04.002 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Sanders, P. [0000-0003-3803-8429] | - |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.